Aditxt, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $1.8K
- Price
- $0.0022
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 13.2M
About
Aditxt, Inc. is a biotechnology firm dedicated to advancing immune system health through innovative mapping and reprogramming techniques. The company's developments include AditxtScore, a platform designed to empower individuals by providing insights into their immune profiles for better management and informed awareness of immune system attacks or dysfunctions. Aditxt also pioneers Apoptotic DNA Immunotherapy, a nucleic acid-based solution that emulates the body's inherent mechanisms for developing self-tolerance to its own tissues. Additionally, Aditxt is actively researching and developing ADi products with diverse therapeutic applications, such as for organ transplant procedures (including skin grafting), various autoimmune conditions, and allergic reactions. The company holds licensing agreements with esteemed institutions like Loma Linda University and Leland Stanford Junior University. Established in 2017, this Richmond, Virginia-headquartered company was initially known as ADiTx Therapeutics, Inc. before rebranding to Aditxt, Inc. in July 2021.
Quick stats
Shares outstanding815.9K
Computed float33.5K
Float / shares4.1%
Cash runway (months)-4.5
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001726711
Websitehttps://www.aditxt.com
AI Summary
AI-generated1/10
majorbullishm and a
Aditxt Signed Definitive Agreement Valuing Ignite Proteomics at Approximately $150 Million
Aditxt signed a definitive agreement to separate its 100%-owned subsidiary, Ignite Proteomics, in a transaction valuing the proteomics business at approximately $150 million.
Ignite will become an independent NYSE-listed company through a newly formed public holding company, while Aditxt remains a separate Nasdaq-listed entity focused on its broader health innovation strategy.
The deal is expected to unlock value for Aditxt shareholders, with Ignite equity holders receiving shares of the new public company based on a $10.00 reference price. Closing is subject to shareholder approvals, SEC registration, and satisfaction of financing conditions.
Red flags
- Transaction subject to customary closing conditions including shareholder approval and minimum cash/financing conditions
- Aditxt must maintain compliance with Nasdaq listing requirements post-separation